This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.
Top Stock Reports for Chevron, Glaxo & T-Mobile
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Glaxo (GSK) and T-Mobile (TMUS).
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
Merck Presents Positive Melanoma Data on Keytruda at ASCO
by Zacks Equity Research
Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.
LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics
by Zacks Equity Research
LabCorp (LH) continues to strengthen hold in the diagnostics space through inorganic means.
Novartis Announces Positive Data on Kisqali and Tasigna
by Zacks Equity Research
Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO.
Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO
by Zacks Equity Research
Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.
LabCorp Extends Aetna Agreement, Expands Diagnostics Business
by Zacks Equity Research
The expanded agreement enables LabCorp (LH) to serve as a preferred national laboratory to almost all of Aetna's members starting Jan 1, 2019.
Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
by Zacks Equity Research
Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.
AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why
by Zacks Equity Research
AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline
The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
by Zacks Equity Research
Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.
AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.
Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View
by Zacks Equity Research
Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.
Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.
HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?
by Zacks Equity Research
Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.
Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid
by Zacks Equity Research
Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.
What's in the Cards for Merck (MRK) This Earnings Season?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Glaxo (GSK) Misses on both Earnings and Revenue in Q1
by Zacks Equity Research
Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.
Sanofi to Divest European Generic Unit, Streamline Business
by Zacks Equity Research
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why
by Zacks Equity Research
Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.
Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
by Zacks Equity Research
Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.